Zelluna ASA

Zelluna ASA is a Norwegian clinical-stage biotechnology company developing a proprietary T cell receptor (TCR)-guided natural killer (NK) cell therapy platform, known as TCR-NK, aimed at treating solid cancers. The company was established in 2016 as Zelluna Immunotherapy AS and is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway. In March 2025, Zelluna Immunotherapy AS combined its business with Ultimovacs ASA to form the present entity, Zelluna ASA, which is a public limited liability company listed on the Oslo Stock Exchange under the ticker ZLNA. Zelluna's scientific premise is that cell therapies have delivered durable "cures" in certain late-stage liquid cancers, but these successes have not translated into solid cancers, which represent by far the largest cancer burden and remain an unsolved challenge. The company's TCR-NK platform is designed to combine TCR guidance with the effector functions of allogeneic NK cells, deploying a mechanism of action intended to be both safe and potent. According to the company, this platform offers unique advantages, including "off-the-shelf" access to an advanced therapy for large patient populations. The company's mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of TCR-guided NK cell therapies. Zelluna is led by a management team of biotech entrepreneurs with deep experience spanning discovery through clinical development of immunotherapies, TCR and cell-based therapies, including marketed products. The team is based in Oslo and is supported by an experienced international board of directors. Zelluna's lead clinical program is ZI-MA4-1, and the company reported in its Second Quarter 2026 presentation that the first patient had been dosed with ZI-MA4-1. The company communicates with investors and the public through quarterly results presentations, press releases and an extraordinary general meeting process, and it maintains a pipeline focused on high-value markets with unmet medical need in solid cancers. Zelluna also emphasizes organizational culture through the "Zelluna Academy," a set of programs and activities intended to support continuous learning and development for individuals and teams across the organization.

Zelluna Immunotherapy AS was established in 2016 and is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway. The company was founded as a clinical-stage immuno-oncology biotech focused on developing novel cell therapies for cancer, with an initial emphasis on T cell receptor (TCR)-guided natural killer (NK) cell therapies, a platform it calls TCR-NK. In August 2018, Namir Hassan joined Zelluna Immunotherapy as Chief Scientific Officer, and in 2019 he became Chief Executive Officer. Geir Christian Melen joined Zelluna Immunotherapy AS in September 2018 as CFO and Finance Director. Under this leadership, the company advanced its TCR-NK platform and built a team of biotech entrepreneurs with experience taking immune-oncology projects from inception through to the clinic, supported by an international board. A major corporate turning point came in March 2025, when Zelluna Immunotherapy AS combined its business with Ultimovacs ASA to form Zelluna. Following this combination, the entity operates as Zelluna ASA, a public limited liability company listed on the Oslo Stock Exchange in Norway under the ticker ZLNA. The combined company retained the TCR-NK focus on solid cancers. By 2026, Zelluna had advanced its lead program, ZI-MA4-1, into the clinic. In its Second Quarter 2026 presentation, the company reported that the first patient had been dosed with ZI-MA4-1. The company also held an Extraordinary General Meeting on September 9, 2026, and disclosed voting rights in connection with that meeting on September 1, 2026. Throughout this period, Zelluna continued to communicate through quarterly results, press releases and investor presentations, and it maintained its mission to eliminate solid cancers by unleashing the most powerful elements of the immune system through TCR-guided NK cell therapies.

• 2026

  Second Quarter 2026 presentation reported the first patient dosed with ZI-MA4-1.

• 2026

  Extraordinary General Meeting held on September 9, 2026; voting rights disclosed on September 1, 2026.

• 2025

  In March, Zelluna Immunotherapy AS combined its business with Ultimovacs ASA to form Zelluna, a public limited liability company listed on the Oslo Stock Exchange (OSE: ZLNA).

• 2025

  Geir Christian Melen assumed the position of Chief Financial Officer on 31 December 2025.

• 2019

  Namir Hassan became Chief Executive Officer of Zelluna Immunotherapy.

• 2018

  Namir Hassan joined Zelluna Immunotherapy as Chief Scientific Officer in August; Geir Christian Melen joined as CFO and Finance Director in September.

• 2016

  Zelluna Immunotherapy AS established, headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway.

Clinical-stage immuno-oncology biotech pioneering off-the-shelf TCR-guided NK cell therapies for solid cancers with unmet medical need in high-value markets.

• TCR-NK cell therapy platform

  A proprietary platform combining T cell receptor (TCR) guidance with the effector functions of allogeneic natural killer (NK) cells, designed to overcome challenges of treating solid cancers and potentially usable across a range of solid cancers with unmet medical need in high-value markets. The platform is intended to provide 'off-the-shelf' access to an advanced therapy for large patient populations.

• ZI-MA4-1

  Zelluna's lead clinical program; the first patient was dosed with ZI-MA4-1 according to the Second Quarter 2026 presentation.

1. 1Zelluna - Homezelluna.com
2. 2About Zelluna - Zellunazelluna.com
3. 3Management - Zellunazelluna.com
4. 4Zelluna ASA (Norway) - Wikidatawikidata.org